<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206020</url>
  </required_header>
  <id_info>
    <org_study_id>19-110-0011</org_study_id>
    <nct_id>NCT04206020</nct_id>
  </id_info>
  <brief_title>Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome</brief_title>
  <acronym>VISTA-2</acronym>
  <official_title>A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study of Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and the Controlled Adverse Environmental (CAE®) Model for the Treatment of Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitotech, SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitotech, SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and
      effective compared to Vehicle for the treatment of the signs and symptoms of dry eye
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over
      the course of approximately 9 weeks. Qualified subjects are randomized 1:1 to receive either
      SkQ1 Ophthalmic Solution, or Placebo (vehicle of SkQ1 Ophthalmic Solution).

      The Primary Endpoints are:

      Change from Baseline (Visit 2) to Visit 5 of Ocular Discomfort;

      Change from Baseline (Visit 2) to Visit 5 of conjunctival fluorescein staining (sum of
      temporal and nasal regions)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment Parallel-group study SkQ1 Ophthalmic Solution versus placebo (vehicle) solution</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Discomfort Scale</measure>
    <time_frame>From baseline to Day 57</time_frame>
    <description>Change of Ocular Discomfort Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Fluorescein Staining</measure>
    <time_frame>From baseline to Day 57</time_frame>
    <description>Change of Conjunctival Fluroscein Staining (sum of temporal and nasal regions)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Discomfort Scale</measure>
    <time_frame>From Baseline to Day 29</time_frame>
    <description>Change from Baseline of Ocular Discomfort on Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Fluorescein Staining</measure>
    <time_frame>From Baseline to Day 43</time_frame>
    <description>Change from baseline of conjunctival fluorescein staining (sum of temporal and nasal regions) to Day 43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film Breakup Time During Controlled Adverse Environment (CAE®)</measure>
    <time_frame>Day 57</time_frame>
    <description>Tear film break-up time pre- to post-CAE®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Fluorescein Staining</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Change from baseline of corneal fluorescein staining in central region on Day 29</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator: SkQ1 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle for SkQ1 Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SkQ1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SkQ1 Ophthalmic Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SkQ1 Vehicle Solution</intervention_name>
    <description>SkQ1 Ophthalmic Solution Vehicle</description>
    <arm_group_label>Placebo Comparator: SkQ1 Vehicle</arm_group_label>
    <other_name>Vehicle for SkQ1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SkQ1 Ophthalmic Solution</intervention_name>
    <description>SkQ1 Ophthalmic Solution</description>
    <arm_group_label>SkQ1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a subject reported history of dry eye;

          -  Have a history of use of eye drops for dry eye symptoms;

          -  Ocular Discomfort;

          -  Schirmer's Test score;

          -  Have corneal fluorescein staining ;

          -  Have lissamine green conjunctival Staining;

          -  Have a conjunctival redness;

        Exclusion Criteria:

          -  Have been previously exposed to previous SkQ1 Ophthalmic Solution treatment;

          -  Have any clinically significant slit lamp findings at Visit 1;

          -  Be diagnosed with an ongoing ocular infection or active ocular inflammation at Visit
             1;

          -  Have had any ocular and/or lid surgeries within 6 months of Visit 1 or any planned
             over the study period;

          -  Have an uncontrolled systemic disease;

          -  Be a woman who is pregnant, nursing or planning a pregnancy;

          -  Be a woman of childbearing potential who is not using an acceptable means of birth
             control;

          -  Have a known allergy and/or sensitivity to the study drug or its components;

          -  Have a condition or be in a situation which the investigator feels may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with the subject's participation in the study;

          -  Be currently enrolled in an investigational drug or device study or have used an
             investigational drug or device within 30 days of Visit 1;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>self-representation</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence T Friedhoff, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mitotech, SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Gould, MS</last_name>
    <phone>(978) 685-8900</phone>
    <phone_ext>9568</phone_ext>
    <email>mgould@oraclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Watson</last_name>
    <phone>(978) 685-8900</phone>
    <phone_ext>9446</phone_ext>
    <email>mwatson@oraclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Eye Institute and Cosmetic Laser</name>
      <address>
        <city>Sun City West</city>
        <state>Arizona</state>
        <zip>85375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mckenna White</last_name>
      <phone>480-889-1211</phone>
      <email>m.white@prgresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul J Hicks, Jr.</last_name>
      <phone>978-475-0705</phone>
      <email>phicks@oraclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye Clinics of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Iverson</last_name>
      <phone>701-478-0061</phone>
      <email>carrie@bergstromeye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Eye Center</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Shelton</last_name>
      <phone>434-947-3984</phone>
      <email>SShelton@piedmonteye.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Dry Eye Syndrome</keyword>
  <keyword>SkQ1</keyword>
  <keyword>KCS</keyword>
  <keyword>Keratoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

